Potential Role of Thrombelastography in the Monitoring of Acquired Factor VIII Inhibitor Hemophilia A: Report on a 78-year-old Woman With Life-threatening Bleedings
Free accessResearch articleFirst published online August, 2009
Potential Role of Thrombelastography in the Monitoring of Acquired Factor VIII Inhibitor Hemophilia A: Report on a 78-year-old Woman With Life-threatening Bleedings
A 78-year-old woman was admitted to our hospital because of syncope associated with hematomas in both legs. Acquired hemophilia A (AHA) with a low antifactor VIII antibodies activity was diagnosed. Whole blood (WB) thrombelastographic profile depicted a hypocoagulable state. During hospitalization, the patient experienced life-threatening bleedings in the neck and in the right thigh. FVIII concentrates and rFVIIa was safe and effective in controlling acute hemorrhagic symptoms. Immunosuppressive therapy was used successfully to eradicate the inhibitor. At discharge, FVIII inhibitor was absent and thrombelastogram showed a normal profile. Our report confirms that AHA is a heterogeneous condition in terms of risk of bleeding. Even though the criteria for the diagnosis of AHA is quite well defined, a laboratory test useful to predict the bleeding risk and monitor the response to treatment is lacking. ROTEM profile appears to be correlated with the response to treatment and with the eradication of the inhibitor.
Lavigne-Lissalde G., Schved JF, Granier C., Villard S.Antifactor VIII antibodies, a 2005 update . Thromb Haemost. 2005;94:760-769.
3.
Solymoss S.Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol. 1998;59:1-4.
4.
Huang YW, Saidi P., Philipp C.Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases. Haemophilia. 2004;10:713-721.
5.
Baudo F., de Cataldo F.Italian Association of Haemophilia Centres (AICE): Register of acquired factor VIII inhibitors (RIIA). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG. 2003;110:311-314.
6.
Kashyap R., Choudhry VP, Mahapatra M., Chumber S., Saxena R., Kaul HLPostpartum acquired haemophilia: clinical recognition and management. Haemophilia. 2001;7:327-330.
7.
Lamy O., Elmiger H., Fiche M., Bauer J., Livio F.Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy. Int J Clin Oncol. 2004;9:130-133.
8.
Kleinman MBAnti-inhibitor coagulant complex for the rescue therapy of acquired inhibitors to factor VIII: case report and review of the literature. Haemophilia. 2002;8: 694-697.
9.
Regina S., Colombat P., Fimbel B., Guerois C., Gruel Y.Acquired inhibitor to factor VIII in a patient with Hodgkin’s disease following treatment with interferon-alpha. Haemophilia. 2001;7:526-527.
10.
Sallah S., Wan JYInhibitors against factor VIII in patients with cancer. Analysis of 41 patients . Cancer. 2001;91:1067-1074.
11.
Fozza C., Bellizzi S., Piseddu G., Porcu A., Dore F., Longinotti M.Acquired hemophilia in a patient affected by acute myeloid leukaemia. Am J Hematol. 2005;79:81-82.
12.
Sallah S., Nguyen NP, Abdallah JM, Hanrahan LRAcquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med. 2000;124:730-734.
13.
Oliveira B. , Arkfeld DG, Weitz IC, Shinada S., Ehresmann G.Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. J Clin Rheumatol. 2007;13:89-91.
14.
Struillou L. , Fiks-Sigaud M., Barrier J., Blat E.Acquired haemophilia and rheumatoid arthritis: success of immunoglobulin therapy. J Intern Med. 1993;233:304-305.
Vignes S., Le Moing V., Meekel P., Papo T., Wechsler B., Godeau P.Acquired hemophilia: a rare complication of Sjogren’s syndrome. Clin Exp Rheumatol. 1996;14: 559-560.
17.
Dannhauser D., Casonato A., Pietrogrande F., et al. Acquired factor VIII:C inhibitor in a patient with Sjogren’s syndrome: successful treatment with steroid and immunosuppressive therapy. Acta Haematol. 1994;91: 73-76.
18.
Lightburn E. , Morand JJ, Graffin B., et al. Pemphigoid and acquired hemophilia . Ann Dermatol Venereol. 2001;128:1229-1231.
19.
Patel RS, Harman KE, Nichols C., Burd RM, Pavord S.Bullous pemphigoid and acquired hemophilia. Postgrad Med J . 2006;82:3.
20.
Franchini M. , Capra F., Nicolini N., et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit. 2007;13:RA55-RA61.
21.
Evans EN, Majer RVAcquired haemophilia: an important but often unrecognised cause of bleeding in elderly people. Brit Med J. 1995;311:679.
22.
Kasper CK, Aledort LM, Aronson L., et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872.
Sorensen B. , Johansen P., Christiansen K., Woelke M., Ingerslev J.Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2003;1:551-558.
25.
Collins PW, Hirsch S., Baglin TP, et al; UK Haemophilia Centre Doctors’ Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109:1870-1877.
26.
Gringeri A., Mannucci PMItalian Association of Haemophilia Centres Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia. 2005;11: 611-619.
27.
Key NS, Nelsestuen GLViews on methods monitoring recombinant factor VIIa in inhibitor patients . Semin Hematol. 2004;41(suppl 1):51-54.
28.
Young G., Blain R., Nakagawa P., Nugent DJIndividualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006;12:598-604.
29.
Abshire T., Kenet G.Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899-909.
30.
Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., Villar A.Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121:21-35.
